TORONTO and WINNIPEG, Jan. 24 /CNW/ - Cangene today announces that the U.S. Food and Drug Administration (“FDA”) has approved Accretropin(TM) (somatropin (rDNA origin)) Injection, Cangene’s recombinant human growth hormone (“rhGH”). The drug is indicated for treatment of pediatric patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone, or treatment of short stature associated with Turner Syndrome in pediatric patients whose epiphyses are not closed. “This is a significant accomplishment. Accretropin(TM) is our first recombinant product approval. Cangene continues to demonstrate that it can take new products from development to approval effectively,” said Dr. John Langstaff, president and CEO of Cangene. “We now have four FDA-approved drugs.”
